Caprock Group LLC Has $4.04 Million Holdings in Astrazeneca Plc $AZN

Caprock Group LLC raised its position in shares of Astrazeneca Plc (NYSE:AZN) by 13.8% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 43,939 shares of the company’s stock after purchasing an additional 5,344 shares during the quarter. Caprock Group LLC’s holdings in Astrazeneca were worth $4,039,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in AZN. Triumph Capital Management bought a new position in shares of Astrazeneca during the 3rd quarter worth approximately $25,000. Bangor Savings Bank boosted its holdings in shares of Astrazeneca by 102.7% during the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after buying an additional 154 shares in the last quarter. Eagle Bay Advisors LLC bought a new position in shares of Astrazeneca during the 4th quarter worth approximately $30,000. Rakuten Investment Management Inc. bought a new position in shares of Astrazeneca during the 3rd quarter worth approximately $31,000. Finally, YANKCOM Partnership bought a new position in shares of Astrazeneca during the 4th quarter worth approximately $31,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Barclays restated an “overweight” rating on shares of Astrazeneca in a report on Tuesday, January 6th. Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. TD Cowen restated a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Wall Street Zen cut Astrazeneca from a “buy” rating to a “hold” rating in a report on Saturday, April 4th. Finally, Citigroup assumed coverage on Astrazeneca in a report on Tuesday, January 27th. They set a “buy” rating on the stock. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Astrazeneca currently has a consensus rating of “Moderate Buy” and an average price target of $102.67.

Astrazeneca Trading Down 1.3%

Shares of AZN opened at $192.35 on Friday. Astrazeneca Plc has a 12-month low of $132.32 and a 12-month high of $212.71. The company has a current ratio of 0.94, a quick ratio of 0.72 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $298.31 billion, a P/E ratio of 33.13, a PEG ratio of 1.47 and a beta of 0.35.

Astrazeneca Dividend Announcement

The company also recently announced a dividend, which was paid on Monday, March 23rd. Investors of record on Friday, February 20th were issued a $1.595 dividend. This represents a dividend yield of 156.0%. The ex-dividend date was Friday, February 20th. Astrazeneca’s dividend payout ratio (DPR) is currently 74.83%.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.